Description | FUNCTION:Requiredforautophagy.ConjugatestoATG12andassociateswithisolationmembranetoformcup-shapedisolationmembraneandautophagosome.Theconjugatedetachesfromthemembraneimmediatelybeforeorafterautophagosomeformationiscompleted.FUNCTION:Mayplayanimportantroleintheapoptoticprocess,possIBLywithinthemodifiedCytoskeleton.Itsexpressionisarelativelylateeventintheapoptoticprocess,occurringdownstreamofcaspaseactivity.SUBCELLULARLOCATION:Cytoplasm.Colocalizeswithnonmuscleactin.ALTERNATIVEPRODUCTS:2namedisoformsproducedbyalternativesplicing.TISSUESPECIFICITY:Ubiquitous.ThemRNAispresentatsimilarlevelsinviableandapoptoticcells,whereastheproteinisdramaticallyhighlyexpressedinapoptoticcells.INDUCTION:Byapoptoticstimuli.PTM:ConjugatedtoATG12;whichisessentialforautophagy,butisnotrequiredforassociationwithisolationmembrane.SIMILARITY:BelongstotheATG5family. |
BatchNo. | Seeproductlabel |
Unitsize | 500µg |
Antigen | AsyntheticpeptidecorrespondingtotheC-terminalofhumanATG-5L.Noimmunogeniccarrierproteinwasconjugatedtotheimmunogen.Instead,AdjukineB(seetheAdjuvantsinBiosensis"productlist)hasbeenusedtoorchestrate/boosttheimmuneresponse. |
OtherNames | Autophagyprotein5;APG5-like;APG5;APG5;Apoptosis-specificprotein;ATG5;APG5L;ASP |
Accession | ATG5_HUMAN |
Producedin | Rabbit |
Purity | ProteinGpurifiedIgG |
Applications | FlowCytometry(2ug/10^6cells),IHC,immunofluorescence,WB.Useadilutionof1:200to1:1000fortheseapplications.Biosensisrecommendsoptimaldilutions/concentrationsshouldbedeterminedbytheenduser. |
Specificity | IHCandwbconfirmedthespecificityforATG5. |
Cross-reactivity | Human,notyettestedinotherspecies. |
Form | Lyophilised |
Reconstitution | Reconstitutein500µlofsterilewater.Centrifugetoremoveanyinsolublematerial. |
Storage | Afterreconstitutionkeepaliquotsat-20ºCforahigherstABIlity,andat4ºCwithanappropriateantibacterialagent.Glycerol(1:1)maybeaddedforanadditionalstability.Avoidrepetitivefreeze/thawcycles. |
ExpiryDate | Sixmonthsafterpurchase |
SpecificReferences | 1.Garrido-MaraverJ.etal(2012)ScreeningofeffectivepharmacologicaltreatmentsforMELASsyndromeusingyeasts,fibroblastsandcybridsmodelsofthediseaseBrJPharmacol.2012Jul2. 2.DelaMataM.etal(2012)RecoveryofMERRFfibroblastsandcybridspathophysiologybyCoenzymeQ₁₀Neurotherapeutics.2012Apr;9(2):446-63. 3.CotánD.etal.(2011)SecondarycoenzymeQ10deficiencytriggersmitochondriadegradationbymitophagyinMELASfibroblastsFASEBJ.2011 |
References | 1.Mizushima,Netal.(2003)IntJBiochemCellBiol.35(5),553-61 2.BaehreckeEH.NatRevMolCellBiol.6(6):505-10.(2005) 3.LumJJ,etal.NatRevMolCellBiol.6(6):439-48.(2005) 4.GreenbergJT.DevCell.8(6):799-801.(2005) |
Biosensis专注于神经科学领域的抗体和试剂的开发,特别是神经营养因子和神经营养因子受体。 近30年来,Biosensis一直是该领域的全球领航者和OEM供应商。除神经营养因子,我们的神经科学产品组合还被广泛用于神经退行性疾病、神经发育和神经代谢的研究。重点研究领域包括阿尔茨海默氏症(AD)、帕金森氏症(PD)和肌萎缩侧索硬化(ALS)疾病,以及自噬和代谢应激障碍,包括肥胖、代谢综合征的研究、神经免疫学和炎症。